TBXT

Across TCGA pan-cancer cohorts, TBXT Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TBXT data layer compared with 20 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TBXT Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBXT expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

BLCA, UCEC, and LIHC are the cancer types where TBXT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.051	0.600	<.001	12	view →
UCEC	OS	Median	All	1.000	0.657	.014	12	view →
LIHC	DFS	Median	All	0.117	0.534	.001	7	view →
LUSC	OS	Median	III,IV	0.505	0.664	.002	7	view →
CESC	OS	Median	II,III,IV	0.447	0.763	.040	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	OS	Median	III,IV	1.000	0.361	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TBXT–BLCA (OS)

Open the BLCA breakdown →